Goat study finds dose-dependent pentoxifylline kinetics

A new goat pharmacokinetics study in Animals reports that pentoxifylline and its active 5-hydroxyhexyl metabolite don’t behave proportionally across intravenous doses of 10, 20, and 40 mg/kg. In the study, plasma concentrations were measured by HPLC after single-dose IV administration, and the highest dose showed lower total clearance and lower steady-state volume of distribution than the 10 and 20 mg/kg groups, pointing to dose-dependent, non-linear disposition rather than simple dose scaling. That matters because pentoxifylline is used in veterinary medicine for its hemorheologic and anti-inflammatory effects, but there’s no FDA-approved animal drug labeled for goats, making any use in this species extra-label and heavily dependent on species-specific pharmacology. (dailymed.nlm.nih.gov)

Why it matters: For veterinarians working with goats, the takeaway is straightforward: increasing the dose may not produce predictable exposure, and extrapolating from lower-dose data could raise the risk of over- or under-dosing. That’s especially relevant in small ruminants, where FDA notes that drug handling can differ meaningfully between sheep and goats, and related work from the same research group has already shown that ascending pentoxifylline doses in goats altered hematologic and biochemical markers, with authors urging caution around repeated administration. A sheep study by overlapping investigators also found dose-dependent changes in pentoxifylline pharmacokinetics, and reported tachycardia, hypersalivation, and agitation at 40 mg/kg. (fda.gov)

What to watch: The next step is whether follow-on studies define a clinically useful goat dosing regimen, safety margin, and, for food animals, residue and withdrawal data. (dergipark.org.tr)